Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Retained Earnings (2016 - 2025)

VYNE Therapeutics' Retained Earnings history spans 10 years, with the latest figure at -$757.7 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 3788600.0% year-over-year to -$757.7 million; the TTM value through Dec 2025 reached -$757.7 million, down 3788600.0%, while the annual FY2025 figure was -$757.7 million, 3788600.0% down from the prior year.
  • Retained Earnings reached -$757.7 million in Q4 2025 per VYNE's latest filing, down from -$745.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $34000.0 in Q3 2024 to a low of -$757.7 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$527.8 million, with a median of -$643.3 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.0% in 2024, then plummeted 3788600.0% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$639.5 million in 2021, then dropped by 3.63% to -$662.7 million in 2022, then skyrocketed by 100.0% to $26000.0 in 2023, then fell by 23.08% to $20000.0 in 2024, then tumbled by 3788600.0% to -$757.7 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Retained Earnings are -$757.7 million (Q4 2025), -$745.5 million (Q2 2025), and -$739.8 million (Q1 2025).